Calliditas Therapeutics AB (publ) (CALT) is a biotherapeutics company engaged in the development and marketing of innovative treatments for hepatic and kidney disorders. The company’s lead product is TARPEYO which is the sole therapeutics used in the reduction of proteinuria.
The price of CALT stock during the regular trading on January 28, 2021, was $19.75 with a significant increase of 5.33%. At last check in the premarket on January 31, 2022, the stock gained further momentum by 2.38%.
CALT: Events and Happenings
CALT reported about the preliminary sales and commercial accessibility of one of its lead products TARPEYO on January 28, 2022. It is used for treating IgA nephropathy. TARPEYO is the pioneer and only FDA-accepted therapeutics in this disorder.
CALT: Key Financials
On November 18, 2021, CALT reported its interim financial results for the three months ended September 30, 2021. Some of the key updates are as follows.
Profit/Loss per Share
Basic and diluted profit per share for the quarter in 2021 was SEK 6.4 million or SEK 0.21 compared to a loss of SEK 138 million or SEK 2.77 in the same period of 2020.
Net Sales
Net sales for the quarter in 2021 were SEK 198.2 million compared to no net sales for the same period of 2020.
Assets
Total current assets recorded for the company were SEK 1256 million.
On November 3, 2021, CALT reported that the management presented at the Virtual American Society of Nephrology Annual Kidney Week 2021 conference held on November 2-7, 2021. On October 7, 2021, CALT reported controlling Genkyotex SA’s 100% share capital.
CALT reported on September 16, 2021, about the continuation of the marketing authorization application assessment of Nefecon by the European Medicine Agency’s Committee for Human Medicinal Products.
Conclusion
CALT stock decelerated 32% from the past six months due to economic downsizing as a result of pandemics. The stockholders are showing their interest because of the latest announcement by the company regarding the commercial availability of TARPEYO. The analysts are predicting it to be a great breakthrough for the company in terms of revenue generation.
